GenScript ProBio Congratulates ABL Bio's IND Clearance of ABL103 Program from MFDS

Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly extends congratulations on this major milestone achievement. In this ABL103 program, GenScript ProBio provided the service of process development & optimization, clinical material manufacturing, and CTD documentation preparation for MFDS IND filing.

Related Keywords

Nanjing ,Jiangsu ,China ,Hong Kong ,Shanghai ,United States ,Netherlands ,South Korea ,Asia Pacific ,Patrick Liu ,Hoon Lee ,Genscript Probio ,Genscript Biotech Corporation ,Emergency Use Authorization ,Sang Hoon Lee ,Script Probio ,Mfds ,Bispecific Antibody ,Avrobio ,Clinical Trial Application ,Genscript ,